The World Health Organization (WHO) today announced its recommendations for influenza vaccine composition for the 2026-2027 northern hemisphere influenza season, a crucial step in preparing for the annual respiratory illness. The recommendations, made after a four-day consultation examining global influenza surveillance data, aim to ensure that vaccines are closely matched to circulating viruses, maximizing protection against severe illness and death. This ongoing process of adaptation is essential, as influenza viruses are notorious for their constant evolution.
Seasonal influenza, commonly known as the flu, remains a significant public health concern worldwide. According to the WHO, there are around a billion cases of seasonal influenza annually, resulting in 3–5 million cases of severe illness and an estimated 290,000 to 650,000 respiratory deaths each year. These updated vaccine recommendations are a direct response to the changing nature of the virus and are intended to mitigate the impact of the upcoming flu season.
The require for updated recommendations was underscored by the emergence of a distinct variant of the A(H3N2) virus in August 2025, classified as J.2.4.1, or “subclade K.” This variant spread rapidly across the globe, contributing to an earlier start to the influenza season in many countries and higher-than-usual levels of activity. ‘Subclade K’ became the dominant influenza virus reported across many regions, highlighting the importance of proactive vaccine adaptation.
Understanding the Recommended Vaccine Strains
The WHO’s recommendations detail specific strains to be included in both egg-based and cell culture-based influenza vaccines. For egg-based vaccines, the recommended strains are: an A/Missouri/11/2025 (H1N1)pdm09-like virus; an A/Darwin/1454/2025 (H3N2)-like virus; and a B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus. For cell culture-, recombinant protein- or nucleic acid-based vaccines, the recommendations are slightly different: an A/Missouri/11/2025 (H1N1)pdm09-like virus; an A/Darwin/1415/2025 (H3N2)-like virus; and a B/Pennsylvania/14/2025 (B/Victoria lineage)-like virus.
Zoonotic Influenza and Pandemic Preparedness
Beyond seasonal strains, the WHO also monitors influenza viruses circulating in animals, known as zoonotic influenza, due to their potential to cause pandemics. Since September 23, 2025, 25 human infections with zoonotic influenza have been reported from six countries. While these cases primarily involved exposure to infected animals, the WHO continues to closely monitor for any signs of human-to-human transmission. The organization also recommended the development of a new candidate vaccine virus (CVV) for an A(H9N2) virus, a proactive measure to enhance pandemic preparedness.
The Global Influenza Surveillance and Response System
These recommendations are a direct result of the work conducted through the WHO’s Global Influenza Surveillance and Response System (GISRS), established in 1952. GISRS is the longest-standing global platform for systematic disease surveillance, bringing together experts from collaborating centers and essential regulatory laboratories worldwide to analyze data and inform vaccine development. “Season after season, constantly evolving influenza viruses circulate globally, showing us how connected our world is. Shared risks require shared action,” said Dr. Tedros Adhanom Ghebreyesus, WHO Director-General.
The process of developing and distributing these vaccines relies on collaboration between the WHO, national vaccine regulatory agencies, and pharmaceutical companies. The goal is to ensure that vaccines are available and accessible to populations around the world, though current vaccine distribution remains uneven, with upper-middle and high-income countries utilizing the majority of doses. Recent assessments by the WHO suggest that improved, next-generation influenza vaccines could prevent up to 18 billion cases of influenza and save up to 6.2 million lives globally between 2025 and 2050.
As the world prepares for the 2026-2027 influenza season, the WHO’s recommendations provide a critical framework for vaccine development and distribution. The ongoing surveillance and adaptation efforts of the GISRS remain essential in protecting global populations from the ever-evolving threat of influenza. The next key date to watch for is the release of updated data from the GISRS following the southern hemisphere influenza season, which will inform further adjustments to vaccine composition as needed.
Have thoughts on the upcoming flu season or the importance of vaccination? Share your comments below, and please share this article with your network to help spread awareness.
